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On 10 April 2008, CV Therapeutics, Inc. of Palo Alto,
California, USA, received approval from the US Food and
Drug Administration (FDA) for the use of Lexiscan®
(regadenoson; CVT-3146), an A2A adenosine receptor
(A2AAdoR) agonist, as a pharmacological stress agent in
conjunction with radionuclide myocardial perfusion imaging
(MPI) in patients unable to undergo adequate exercise stress.
Lexiscan® has a higher affinity for A2A adenosine
receptors than adenosine and is a more potent coronary
vasodilator. It preferentially dilates coronary arteries rela-
tive to other vascular beds [1], probably due to the high
density of A2AAdoR in the coronary arteries and high
receptor reserve at that site [2], resulting in maximal
vasodilation induced by the activation of a small percentage
of these receptors.
MPI is commonly used in the clinical setting for the
diagnosis of coronary artery stenosis. The rationale for the
use of pharmacologic vasodilators in MPI is based on
the differential blood flow response in normal vs. diseased
coronary arteries, resulting in a coronary-steal phenome-
non. The production of myocardial perfusion defects is
reflected in nonhomogeneous distribution of a radiophar-
maceutical, which is administered subsequent to the
vasodilator agent, detected by a gamma camera, and
quantified by a computer utilizing specific software.
Adenosine and dipyridamole (an adenosine transport
blocker that elevates extracellular adenosine levels) have
previously been used as pharmacologic stressors; however,
the use of both is associated with adverse effects caused by
the activation of A1AdoR in addition to the A2AAdoR. For
example, first-degree atrioventricular (AV) block occurs in
approximately 10% and second- or third-degree AV block
in approximately 4% of patients due to the inhibitory effect
of adenosine on the AV nodal conduction [3].
Lexiscan® (Fig. 1), given as a bolus injection, increases
coronary blood flow velocity by more than 2.5-fold above
baseline for at least 2 min [4], which is ample time for the
administration and distribution of a radiopharmaceutical.
Experience with regadenoson (Lexiscan®) has shown that
it is well-tolerated, as effective as adenosine as a pharmaco-
logicstressorinMPI,andassociatedwithlesssideeffectsthan
adenosine [5]. Lexiscan® is approved 19 and 13 years after
the approval of Adenocard® (intravenous adenosine) in 1989
for conversion of paroxysmal supraventricular tachycardia
(PSVT) to sinus rhythm and Adenoscan® in 1995 as a
pharmacological stress agent in MPI, respectively. The
approval of Lexiscan® represents an important milestone in
the adenosine research field. It is the first synthetic adenosine
receptor ligand approved for medical use. The approval
should serve as an impetus for the development of others
adenosine and purine nucleotide analogs as novel diagnostic
and therapeutic agents.
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Fig. 1 Lexiscan® (CVT-3146):
Adenosine, 2-[4-[(methylamino)
carbonyl]-1H-pyrazol-1-yl]-,
monohydrate
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